PubMed Health⌕ Search

Biomedical subjects

C Bános

Publications and source records attributed to C Bános.

At least 19 recordsLinked to original sources
PubMed1992

Biologic markers in blood reflecting thyroid hormone effect at peripheral tissue level in patients receiving levothyroxine replacement for hypothyroidism.

Plasma fibronectin, serum procollagen-III-peptide and sex-hormone binding globulin as not specific markers of thyroid hormone effect at peripheral tissue level were determined and their values were related with serum levels of TSH, free-thyroxine and triiodothyronine during levothyroxine sodium replacement therapy for hypothyroidism. Low levels of biologic markers characteristic of hypothyroidism were normalized in consequence of hormone replacement and a negative correlation between their serum levels and TSH concentration was demonstrated in most subjects. However, in some patients a discrepancy in the response to levothyroxine between the pituitary and other target organs could be revealed. Additional evidence was disclosed that the pituitary thyrotroph sensitizes a minor decrease in serum thyroxine level, which would not be recognized by other target organs. Furthermore, it was revealed that during L-T4 replacement therapy in a large fraction of patients with subnormal serum TSH concentration blood levels of the measured markers often exceeded the upper limit of the normal range indicating the possibility of "tissue"-thyrotoxicosis beside the pituitary in other target organs, too. According to the present study which takes into consideration markers reflecting end-organ responsiveness to thyroid hormones it is recommended to adjust the dose of levothyroxine to maintain serum TSH in the normal range. For patients with subnormal TSH concentration a close follow-up is obligatory and in case od concomitantly raised free-thyroxine level the reduction of the levothyroxine dosage is proposed.

Adult↗
PubMed1991

[Biological markers reflecting peripheral effects of thyroid hormones in autonomous thyroid adenoma].

In some patients with functioning thyroid autonomous nodules preclinical hyperthyroidism is detected. It is important to know, whether in this intermediate clinical state beside the suppression of pituitary TSH secretion other target organs are also affected by serum free-thyroxine and free-triiodothyronine levels still within the normal range. Determining some sensitive, but not specific biologic markers reflecting the impact of thyroid hormones at the peripheral tissue level, it was demonstrated that in the group of preclinical hyperthyroidism the mean level of plasma fibronectin exceeded that of the controls (mean +/- S. D.: 583.5 +/- 163.9 vs. 424.2 +/- 84.1 micrograms/ml, p less than 0.001), serum procollagen-III-peptide concentration was already significantly raised, though its value was still within the normal range (mean +/- S. D.: 0.73 +/- 0.17 vs. 0.57 +/- 0.16 U/ml, p less than 0.05), conversely, mean sex-hormone binding globulin level was the same as in euthyroid controls (mean +/- S. D. 47.4 +/- 18.2 vs. 48.3 +/- 16.3 nmol/l). The value of all three parameters was significantly elevated in patients with toxic nodular goiter. Based on the results of this study "tissue"-thyrotoxicosis is suspected in some patients with preclinical hyperthyroidism, which may have therapeutical implications.

Adult↗
PubMed1991

Biologic blood markers reflecting thyroid hormone effect at peripheral tissue level in patients receiving levothyroxine replacement for hypothyroidism.

Plasma fibronectin, serum procollagen-III-peptide and sex-hormone-binding globulin as non-specific markers of thyroid hormone effect at peripheral tissue level were determined and their values were related with serum levels of TSH, free-thyroxine and triiodothyronine during levothyroxine sodium replacement therapy for hypothyroidism. Low levels of biologic markers characteristic of hypothyroidism were normalized in consequence of hormone replacement and a negative correlation between their serum levels, and TSH concentration was demonstrated in most subjects. However, in some patients a discrepancy in the response to levothyroxine between the pituitary and other target organs was revealed. Additional evidence was disclosed that the pituitary thyrotroph sensitizes a minor decrease in serum thyroxine level, which would not be recognized by other target organs. Furthermore, it was revealed that during L-T4 replacement therapy in a large fraction of patients with subnormal serum TSH concentration blood levels of the measured markers often exceeded the upper limit of the normal range indicating a possibility of "tissue" thyrotoxicosis, besides the pituitary, in other target organs, too. According to the present study, which takes into consideration markers reflecting end-organ responsiveness to thyroid hormones, it is recommended to adjust the dose of levothyroxine to maintain serum TSH in the normal range. For patients with subnormal TSH concentration a close follow-up is obligatory and in case of concomitantly raised free-thyroxine level the reduction of the levothyroxine dosage is proposed.

Adult↗
PubMed1990

[Serum sex hormone-binding globulin levels in thyroid diseases].

Synthesis of "sex-hormone binding globulin" is influenced by the thyroid hormones and its concentration in the serum may be a marker of the thyroid hormone effect at the peripheral tissue (liver) level. Compared to euthyroid controls serum "sex-hormone binding globulin" concentration is elevated in overt hyperthyroidism (141.6 +/- 37.6 vs 48.3 +/- 16.2 nmol/l; p less than 0.001), conversely, its mean level is decreased in the hypothyroid group of patients (24.9 +/- 14.8 vs 48.3 +/- 16.2; p less than 0.001). In the group of subclinical hyperthyroidism the mean value of "sex-hormone binding globulin" corresponds to that in control subjects (47.4 +/- 16.8), while its serum level is near the lower border of the normal range in subclinical hypothyroidism (33.6 +/- 6.1 vs 48.3 +/- 16.2; p less than 0.01). During thyroid hormone replacement for hypothyroidism measurement of serum "sex-hormone binding globulin" may help to assess the response of the target organs to the hormone therapy. In patients with peripheral thyroid hormone resistance serum "sex-hormone binding globulin" level is within the normal range (51.3 +/- 9.8), its determination supports the diagnosis of this disease.

Adult↗
PubMed1990

The measurement of the serum sex-hormone binding globulin in various thyroid diseases.

Synthesis of "sex-hormone binding globulin" (SHBG) is influenced by thyroid hormones and its concentration in the serum of female subjects may be a marker of thyroid hormone effect at the peripheral tissue (liver) level. Compared to the levels found in euthyroid females (n = 46), the mean (+/- S.D.) serum SHBG concentration was found elevated in overt hyperthyroidism (Graves' disease: n = 56; 141.6 +/- 37.6 vs. 48.3 +/- 16.2; toxic nodular goiter: n = 16; 119.9 +/- 50.7 vs. 48.3 +/- 16.2 nmol/l; P less than 0.001). In contrast, it was decreased in manifest hypothyroidism (n = 25; 24.9 +/- 14.8 vs. 48.3 +/- 16.2; P less than 0.001). In the group of preclinical hyperthyroidism (n = 43), despite suppressed TSH secretion, the serum value of SHBG was normal (47.4 +/- 16.8), while its serum level approached the lower border of the normal range in subclinical hypothyroidism (n = 10; 33.6 +/- 6.1 vs 48.3 +/- 16.2 nmol/l; P less than 0.01). Data indicate that the pituitary responds more sensitively than the liver to a slight change of the serum thyroid hormone level. During thyroid hormone replacement for hypothyroidism, measurement of serum SHBG may provide help to assess the response of the target organ to the given therapy. In patients with generalized resistance to thyroid hormone, the serum SHBG level is within the normal range (51.3 +/- 9.8 nmol/l), thus, its determination supports the diagnosis of this disease.

Biomarkers↗
PubMed1989

[Thyroid function in severe non-thyroidal diseases].

The aim of the present study was to find out whether a change in the function of the pituitary-thyroid axis can be revealed in a relatively homogenous group of hematological patients. To clarify this problem serum levels of total-thyroxine and triidothyronine, free-thyroxine and free-triiodothyronine, reverse-triidothyronine and thyrotropin were detected in these patients. The majority of subjects with chronic myelogenous leukemia (in the remission phase) have normal pituitary-thyroid function, however a change in the peripheral metabolism of thyroxine can be revealed. Longitudinal studies in patients with acute myelogenous leukemia indicate that in some cases with the progression of the disease serum TSH and thyroid hormone levels decrease referring to secondary hypothyroidism and in these cases the measurement of serum free-thyroxine content by an analogue tracer method is not recommended. On the basis of the investigational results it is stated that in hematological patients the pituitary-thyroid function is influenced by the phase of illness and by the results of the given treatment.

Humans↗
PubMed1989

Thyroid function in severe "nonthyroidal illness". Longitudinal studies in haematological patients.

It is known that in severe nonthyroidal illness the regulation of thyroid function, the distribution and metabolism of thyroid hormones may change. The present study aimed at clarifying whether a change in the function of the pituitary-thyroid axis can be detected in an approximately homogeneous group of haematological patients, and how it is correlated with the various phases of the disease and with the therapeutic result. Studies were performed on patients with chronic and acute myelogenous leukaemia: serum levels of total thyroxine and triiodothyronine, free thyroxine and triiodothyronine, reverse triiodothyronine and thyrotropic hormone were determined. Apart from a few cases, there was no dysfunction of the pituitary-thyroid axis in chronic leukaemic patients being in the remission phase. However, the peripheral thyroxine metabolism may be altered. The longitudinal studies on acute myelogenous leukaemic patients indicate that, with the progression of the disease, serum TSH and thyroid hormone levels were reduced in a part of the cases and it is not justified to assess the free serum thyroxine level by an analogue-tracer method in this disease. The examinations have revealed that the various phases of the clinical picture as well as the therapeutic results considerably influence the function of the pituitary-thyroid axis. It seems reasonable to consider these findings in the other severe nonthyroidal illnesses as well.

Adult↗
PubMed1987

Examination of serum thyrotropic hormone level by 'supersensitive' immunoradiometric assay in functioning thyroid adenoma.

TSH determination by immunoradiometric assay (IRMA) has enabled the detection of subnormal levels of TSH and has thus opened up new vistas in the differentiation between euthyroidism and hyperthyroidism. The present investigations have proved that in patients with autonomous functioning thyroid adenoma with progressive clinical trend, when 'non-toxic' nodular goitre transforms into toxic adenoma, the basal serum TSH level is gradually decreasing. In case of a functioning thyroid adenoma detected by scintigraphy, the basal TSH concentration of the serum over 0.3 mU/l indicates euthyroidism. In preclinical hyperthyroidism, similarly to toxic adenoma, the serum thyroid hormone determination contributes to differentiating between the two clinical states. The IRMA for TSH determination makes it unnecessary, in the majority of cases, to perform the TRH (thyreotrop-releasing hormone) loading-test, which is needed only if the basal serum TSH level is in the borderline range, i.e. between 0.1 and 0.3 mU/l.

Adenoma↗
PubMed1986

Effects of methysergide, bromocriptine and naloxone on prolactin, growth hormone and TSH release induced by D-Met2,Pro5-enkephalinamide in man.

D-Met2,Pro5-enkephalinamide (EA) 10 mg, given SC, induced a dramatic rise in serum prolactin (PRL) and growth hormone (GH) levels in healthy male volunteers. The TSH content was also moderately elevated. Naloxone 0.8 mg administered IV abolished these effects. Bromocriptine 2.5 mg given per os also antagonized EA-induced PRL and TSH release but potentiated the GH surge. Methysergide 2.0 mg administered orally partially reversed EA-elicited PRL release, further augmented GH liberation and did not modify TSH output. The data indicate that inhibition of the dopaminergic tone and/or activation of certain serotonergic mechanisms play an important role in the EA-induced release of PRL and TSH. However, primarily other neurotransmitters might mediate the GH liberation elicited by this opioid peptide.

Adult↗
PubMed1986

Interplay of various factors in glucose-induced hyperkalemia during captopril treatment.

The effect of angiotensin converting enzyme inhibition by captopril (CAP) on serum potassium (SK) changes was studied during a three-hour glucose tolerance test (GTT) in recumbent and upright positions in 16 patients with drug-resistant hypertension. An elevation of SK in the upright posture occurred in the course of GTT during CAP treatment in 50% of the patients (Group I) even without consistent changes in baseline SK. In Group II a qualitatively normal glucose-induced hypokalemic response was obtained. Aldosterone was suppressed by CAP, predominantly in the upright position in Group I due to the significant interaction between the drug and posture. Significant inverse correlations were found in Group I between glucose-induced serum potassium changes and basal glomerular filtration rate. A similar correlation was found also with serum insulin in the whole patient material. It was concluded that the interplay of various factors, CAP, upright posture and impaired renal functions resulting in suppression of aldosterone and insulin played a role in the paradoxical glucose-induced serum potassium elevation.

Adult↗